219 related articles for article (PubMed ID: 35948546)
1. Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus.
Koch J; Schober SJ; Hindupur SV; Schöning C; Klein FG; Mantwill K; Ehrenfeld M; Schillinger U; Hohnecker T; Qi P; Steiger K; Aichler M; Gschwend JE; Nawroth R; Holm PS
Nat Commun; 2022 Aug; 13(1):4689. PubMed ID: 35948546
[TBL] [Abstract][Full Text] [Related]
2. The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma.
Schober SJ; Schoening C; Eck J; Middendorf C; Lutsch J; Knoch P; von Ofen AJ; Gassmann H; Thiede M; Hauer J; Kolk A; Mantwill K; Gschwend JE; Burdach SEG; Nawroth R; Thiel U; Holm PS
Clin Cancer Res; 2023 May; 29(10):1996-2011. PubMed ID: 36892582
[TBL] [Abstract][Full Text] [Related]
3. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
4. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
5. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer.
Kim S; Armand J; Safonov A; Zhang M; Soni RK; Schwartz G; McGuinness JE; Hibshoosh H; Razavi P; Kim M; Chandarlapaty S; Yang HW
Cell Rep; 2023 Nov; 42(11):113198. PubMed ID: 37865915
[TBL] [Abstract][Full Text] [Related]
6. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
[TBL] [Abstract][Full Text] [Related]
7. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
8. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC
Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101.
Song X; Zhou Y; Jia R; Xu X; Wang H; Hu J; Ge S; Fan X
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2626-35. PubMed ID: 20007825
[TBL] [Abstract][Full Text] [Related]
10. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
11. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.
Nettelbeck DM
J Mol Med (Berl); 2008 Apr; 86(4):363-77. PubMed ID: 18214411
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells.
Song X; Wang H; Jia R; Cun B; Zhao X; Zhou Y; Xu X; Qian G; Ge S; Fan X
Int J Mol Sci; 2012; 13(9):10736-10749. PubMed ID: 23109819
[TBL] [Abstract][Full Text] [Related]
13. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Bhattacharyya M; Francis J; Eddouadi A; Lemoine NR; Halldén G
Cancer Gene Ther; 2011 Oct; 18(10):734-43. PubMed ID: 21836633
[TBL] [Abstract][Full Text] [Related]
14. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
Radhakrishnan S; Miranda E; Ekblad M; Holford A; Pizarro MT; Lemoine NR; Halldén G
Hum Gene Ther; 2010 Oct; 21(10):1311-25. PubMed ID: 20497039
[TBL] [Abstract][Full Text] [Related]
16. Modification of the DNA damage response by therapeutic CDK4/6 inhibition.
Dean JL; McClendon AK; Knudsen ES
J Biol Chem; 2012 Aug; 287(34):29075-87. PubMed ID: 22733811
[TBL] [Abstract][Full Text] [Related]
17. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway.
Cascallo M; Alonso MM; Rojas JJ; Perez-Gimenez A; Fueyo J; Alemany R
Mol Ther; 2007 Sep; 15(9):1607-15. PubMed ID: 17579575
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma.
Xiao J; Liang J; Fan J; Hou P; Li X; Zhang H; Li K; Bu L; Li P; He M; Zhong Y; Guo L; Jia P; Xiao Q; Wu J; Peng H; Li C; Xing F; Guo D
Cancer Res; 2022 Sep; 82(18):3359-3374. PubMed ID: 35792620
[TBL] [Abstract][Full Text] [Related]
19. STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy.
Hindupur SV; Schmid SC; Koch JA; Youssef A; Baur EM; Wang D; Horn T; Slotta-Huspenina J; Gschwend JE; Holm PS; Nawroth R
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046095
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.
Pascual-Pasto G; Bazan-Peregrino M; Olaciregui NG; Restrepo-Perdomo CA; Mato-Berciano A; Ottaviani D; Weber K; Correa G; Paco S; Vila-Ubach M; Cuadrado-Vilanova M; Castillo-Ecija H; Botteri G; Garcia-Gerique L; Moreno-Gilabert H; Gimenez-Alejandre M; Alonso-Lopez P; Farrera-Sal M; Torres-Manjon S; Ramos-Lozano D; Moreno R; Aerts I; Doz F; Cassoux N; Chapeaublanc E; Torrebadell M; Roldan M; König A; Suñol M; Claverol J; Lavarino C; Carmen de T; Fu L; Radvanyi F; Munier FL; Catalá-Mora J; Mora J; Alemany R; Cascalló M; Chantada GL; Carcaboso AM
Sci Transl Med; 2019 Jan; 11(476):. PubMed ID: 30674657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
